ALLMedicine™ Ca 19-9 Center

Feb 17th, 2021 - We have previously identified tissue methylated DNA markers (MDMs) associated with pancreatic ductal adenocarcinoma (PDAC). In this case-control study, we aimed to assess the diagnostic performance of plasma MDMs for PDAC. Thirteen MDMs(GRIN2D, CD...

Jan 25th, 2021 - Lung cancer (LC) is top-ranked in cancer incidence and is the leading cause of cancer death globally. Combining serum biomarkers can improve the accuracy of LC diagnosis. The identification of the best potential combination of traditional tumor ma...

Jan 12th, 2021 - Novel biomarkers and molecular monitoring tools hold potential to improve outcome for patients following resection of pancreatic ductal adenocarcinoma (PDAC). We hypothesized that the combined longitudinal analysis of mutated cell-free plasma KRAS...

Jan 8th, 2021 - Old Dog, New Tricks: Use of CA 19-9 for Early Diagnosis of Pancreatic Cancer.|2021|Modi S,Kir D,Saluja AK,|

Jan 1st, 2021 - Pancreatic ductal adenocarcinoma (PDAC) is associated with a hypercoagulable state and high mortality. Increases in the plasma levels of tumor marker carbohydrate antigen (CA) 19-9 are used in diagnosis and follow-up but have also been reported to...

Feb 17th, 2021 - We have previously identified tissue methylated DNA markers (MDMs) associated with pancreatic ductal adenocarcinoma (PDAC). In this case-control study, we aimed to assess the diagnostic performance of plasma MDMs for PDAC. Thirteen MDMs(GRIN2D, CD...

Jan 25th, 2021 - Lung cancer (LC) is top-ranked in cancer incidence and is the leading cause of cancer death globally. Combining serum biomarkers can improve the accuracy of LC diagnosis. The identification of the best potential combination of traditional tumor ma...

Jan 12th, 2021 - Novel biomarkers and molecular monitoring tools hold potential to improve outcome for patients following resection of pancreatic ductal adenocarcinoma (PDAC). We hypothesized that the combined longitudinal analysis of mutated cell-free plasma KRAS...

Jan 8th, 2021 - Old Dog, New Tricks: Use of CA 19-9 for Early Diagnosis of Pancreatic Cancer.|2021|Modi S,Kir D,Saluja AK,|

Jan 1st, 2021 - Pancreatic ductal adenocarcinoma (PDAC) is associated with a hypercoagulable state and high mortality. Increases in the plasma levels of tumor marker carbohydrate antigen (CA) 19-9 are used in diagnosis and follow-up but have also been reported to...

Mar 27th, 2018 - Neoadjuvant Therapy Case Continued The patient is referred to oncology. Blood work reveals a CA 19-9 level of 100 U/mL (reference range < 35 U/mL) and a staging CT scan of the chest reveals a benign-appearing 3-mm nodule (no prior imaging for comp.

Nov 8th, 2015 - Changing the standard sequence of treatment for operable pancreatic cancer could improve survival for some patients, say researchers. Some patients with operable disease and elevated levels of the CA 19-9 biomarker should receive chemotherapy firs...

Nov 8th, 2015 - Changing the standard sequence of treatment for operable pancreatic cancer could improve survival for some patients, say researchers. Some patients with operable disease and elevated levels of the CA 19-9 biomarker should receive chemotherapy firs...

May 20th, 2014 - A biomarker panel distinguished individuals with pancreatic cancer from those who were healthy, had benign pancreatic cysts, or had chronic pancreatitis with about 90% accuracy, based on analyses of two cohorts. The panel, which tests for the know.

Discussion In this retrospective multicenter study, the largest reported to date, PS and baseline CEA and CA 19-9 levels were the only independent prognostic factors for PFS and/or OS. PS had previously been identified as an independent prognostic...